Aclaris Therapeutics shares torpedo on underwhelming dermatitis trial results
- Aclaris Therapeutics shares plunged more than 24% Wednesday after the company's mild to severe atopic dermatitis (AD) treatment received disappointing topline results. The results from the 4-week Phase 2b trial of its ATI-1777 treatment were not statistically superior to the Phase 2a trial, according to chairman Neal Walker added.
- 01/10/2024
|
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
- Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
- 01/04/2024
|
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
- Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
- 12/06/2023
|
Penny Stocks To Buy Now? 5 Under $5 To Watch This Week
- Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract interest from new traders.
- 12/05/2023
|
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 12/04/2023
|
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
- Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/16/2023
|
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
- Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
- 11/14/2023
|
Aclaris Therapeutics pulls arthritis drug research program; shares plummet
- Aclaris Therapeutics shares fell almost 90% after the biopharmaceutical company announced it is no longer continuing with the development of its rheumatoid arthritis therapeutic zunsemetinib. The company said that its Phase 2b study of zunsemetinib did not meet its primary or secondary endpoints as there was no notable differentiation between zunsemetinib and placebo across any measures of efficacy after 12 weeks.
- 11/13/2023
|
Aclaris Therapeutics to stop development of rheumatoid arthritis drug
- Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.
- 11/13/2023
|
Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer
- Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to replicate or improve the effects of expensive biologics. ACRS has a lead asset, zunsemetinib, in phase 2 trials for rheumatoid arthritis and psoriatic arthritis, with other assets in early stages.
- 09/28/2023
|
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
- WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.
- 09/20/2023
|
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
- An analyst raised his price target on the biotech. He also maintained his buy recommendation on the stock.
- 09/14/2023
|
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
- Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.31 per share a year ago.
- 08/07/2023
|
Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch
- Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid arthritis market is expected to reach $33.3 billion by 2030. Results from the phase 2a study using zunsemetinib for the treatment of patients with psoriatic arthritis are expected to be released by the 1st half of 2024.
- 07/11/2023
|
2 Low-Priced Stocks That Could Make You Richer
- Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.
- 06/26/2023
|
Why Aclaris Therapeutics Topped the Market on Tuesday
- The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market.
- 06/13/2023
|
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
- WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in two healthcare investor conferences in June.
- 06/02/2023
|
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
- Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.31 per share a year ago.
- 05/08/2023
|
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
- WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets.
- 05/02/2023
|
3 Biotech Stocks to Sell Before They're 6 Feet Under
- In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.
- 04/24/2023
|
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.
- 03/27/2023
|
These 2 Biotech Stocks Made Big Monday Moves
- Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.
- 03/06/2023
|
Why Aclaris Therapeutics Is Crashing Today
- Aclaris' phase 2a clinical study of zunsemetinib in treating a chronic skin condition didn't meet its primary or secondary endpoints. The company continues to move forward with other clinical studies for the experimental drug targeting other skin conditions.
- 03/06/2023
|
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
- WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will participate in two November healthcare investor conferences.
- 11/10/2022
|
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, which will be available on-demand beginning on Monday, September 12, 2022 at 7:00 a.m. ET. Management will be available September 12th throughout the day for virtual 1x1 meetings.
- 08/30/2022
|
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
- Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/15/2022
|
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
- Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
- 07/08/2022
|
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
- Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 06/20/2022
|
Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?
- Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.
- 06/06/2022
|
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
- WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the day for virtual 1x1 meetings.
- 05/16/2022
|
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
- WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET. Management will be available February 16th throughout the day for virtual 1x1 meetings.
- 02/02/2022
|
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
- WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.
- 12/27/2021
|
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
- WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:
- 11/03/2021
|
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2021
|
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
- WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).
- 08/27/2021
|
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
- WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update.
- 08/05/2021
|
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2021
|
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
- Tuesday's futures were fairly positive after a somewhat mixed start to the week.
- 06/15/2021
|
Aclaris Announces Pricing of Public Offering of Common Stock
- WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions.
- 06/09/2021
|
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
- Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
- 06/09/2021
|
Aclaris Announces Proposed Public Offering of Common Stock
- WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- 06/08/2021
|
RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday
- The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.
- 06/08/2021
|
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
- Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area and Severity Index (mEASI) score at week four.
- 06/08/2021
|
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/07/2021
|
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
- WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2021 and provided a corporate update.
- 05/07/2021
|
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
- Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
- 03/02/2021
|
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
- Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
- 01/20/2021
|
Aclaris Announces Pricing of Public Offering of Common Stock
- WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 822,557 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $96.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. The offering is expected to close on or about January 22, 2021, subject to customary closing conditions.
- 01/20/2021
|
ACRS Stock Price Increases 220.24%: Why It Happened
- The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) increased by 220.24% today. This is why it happened.
- 01/19/2021
|
Aclaris Announces Proposed Public Offering of Common Stock
- WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- 01/19/2021
|
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
- Investors are excited about the biotech's clinical trial results.
- 01/19/2021
|
Aclaris Therapeutics stock triples after positive data on arthritis treatment
- Aclaris Therapeutics stock triples after positive data on arthritis treatment
- 01/19/2021
|
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
- Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today appeared first on InvestorPlace.
- 01/19/2021
|
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
- A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV (NASDAQ: MRUS) announced a R&D collaboration and licensing agreement with large-cap pharma Eli Lilly And Co (NYSE: LLY) for developing up to three CD-engaging T-cell redirecting bispecific antibody therapies for oncology indications.
- 01/19/2021
|
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
- Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.
- 01/19/2021
|
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
- WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board consisting of Stanley Cohen, MD, Marco Colonna, MD, James Krueger, MD, PhD, and Michael Weinblatt, MD.
- 12/15/2020
|
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
- WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings.
- 11/16/2020
|
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
- WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2020 and provided a corporate update.
- 11/04/2020
|
Aclaris Therapeutics Inc (NASDAQ:ACRS) Expected to Post Earnings of -$0.26 Per Share
- Equities analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post earnings per share of ($0.26) for the current quarter, according to Zacks. Three analysts have made estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.30). Aclaris Therapeutics reported earnings per share of ($0.56) during the same quarter last […]
- 08/22/2020
|
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
- Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 08/13/2020
|
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
- Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/07/2020
|
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
- •First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis •First Subject Dosed in Phase 2a Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19 •Clinical Trial of ATI-1777, an Investigational “Soft” Topical JAK 1/3 Inhibitor, to Proceed in Patients with Moderate to Severe Atopic Dermatitis WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2020 and provided research and development (R&D) and business highlights.“As the pandemic evolves, our team has continued to work hard to make the appropriate business adjustments, advance our pipeline and execute through these uncertain times,” said Dr. Neal Walker, President and CEO of Aclaris. “In the second quarter, we dosed the first subject in our Phase 2a trial of ATI-450 as a potential treatment for moderate to severe rheumatoid arthritis. We are also proud to be participating in the effort to find effective therapeutics for COVID-19 by supporting an investigator-initiated clinical trial of ATI-450 for cytokine release syndrome in hospitalized patients with COVID-19 and the first subject has been dosed in this trial. In addition, we are progressing with the first-in-human trial of ATI-1777 in patients with moderate to severe atopic dermatitis. We look forward to continuing to execute on our clinical development plans.”R&D Highlights: The global outbreak of COVID-19 continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its regulatory and research and development activities listed below. * ATI-450, an investigational oral small molecule MK2 inhibitor compound: * ATI-450-RA-201: An ongoing Phase 2a trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis. * This trial was initiated in March 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment. Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, Aclaris is actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, Aclaris now anticipates reporting data from this trial in the first half of 2021. * ATI-450-CAPS-201: Aclaris expects to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome (CAPS), an IL1β-driven disease, in the second half of 2020. * IIT-2020-ATI-450-COVID-19: An ongoing investigator-initiated Phase 2a, randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy, as a potential treatment for cytokine release syndrome in 36 hospitalized patients with COVID-19. Aclaris is providing funding and clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial. The primary endpoint in this trial is the proportion of subjects who are free from respiratory failure by day 14. * The first subject was dosed in August 2020. * ATI-1777, an investigational topical “soft” Janus Kinase (JAK) 1/3 inhibitor compound: * Aclaris submitted an Investigational New Drug (IND) Application for ATI-1777 for the treatment of moderate to severe atopic dermatitis (AD) in June 2020 and now plans to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe AD. * ATI-1777-AD-201: Aclaris expects to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020. The primary endpoint will assess efficacy at four weeks. * ATI-2138, an investigational oral ITK/TXK/JAK3 (ITJ) inhibitor compound: * Aclaris is developing ATI-2138 as a potential treatment for psoriasis and/or inflammatory bowel disease and expects to submit an IND for ATI-2138 in 2021.Business Development Highlights: * Aclaris continues to pursue strategic alternatives, including seeking partners for: * A-101 45% Topical Solution: to obtain regulatory approval and commercialize A-101 45% Topical Solution, an investigational compound, as a potential treatment for common warts (verruca vulgaris); * ATI-501 & ATI-502: to further develop, obtain regulatory approval and commercialize ATI-501 (oral) and ATI-502 (topical), investigational JAK 1/3 inhibitor compounds, as potential treatments for alopecia; and * ESKATA: to commercialize ESKATA® (hydrogen peroxide) topical solution, 40% (w/w).Financial Highlights:Liquidity and Capital ResourcesAs of June 30, 2020, Aclaris had aggregate cash, cash equivalents and marketable securities of $68.1 million compared to $75.0 million as of December 31, 2019. For the quarter and six months ended June 30, 2020, net cash used in operating activities was $10.8 million and $17.6 million, respectively. As of June 30, 2020, Aclaris had approximately 42.7 million shares of common stock outstanding.Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to fund its operations through the first quarter of 2022, without giving effect to any potential business development transactions or financing activities.Second Quarter 2020 and Year-to-Date Financial Results * The accompanying consolidated statements of operations and selected consolidated balance sheet data have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to Aclaris’ commercial products as discontinued operations. * Net loss was $11.6 million for the second quarter of 2020, compared to $49.9 million for the second quarter of 2019, and was $27.2 million for the six months ended June 30, 2020, compared to $87.4 million for the six months ended June 30, 2019. * Total costs and expenses from continuing operations for the second quarter of 2020 were $13.4 million, compared to $44.5 million for the second quarter of 2019, and were $30.3 million for the six months ended June 30, 2020, compared to $72.8 million for the six months ended June 30, 2019. * Total costs and expenses in the second quarter of 2020 included non-cash stock-based compensation expense of $3.3 million, compared to $4.6 million in the prior year period. * Total costs and expenses for the six months ended June 30, 2020 included non-cash stock-based compensation expense of $6.8 million, compared to $8.9 million in the prior year period. * Recorded a non-cash goodwill impairment charge of $18.5 million for the quarter and six months ended June 30, 2019. There were no impairment charges in either period in 2020. * R&D expenses were $6.5 million and $15.9 million for the quarter and six months ended June 30, 2020, respectively, compared to $17.5 million and $37.2 million for the quarter and six months ended June 30, 2019, respectively. * The quarter-over-quarter decrease of $11.1 million was primarily the result of the substantial completion of Aclaris’ various Phase 2 clinical trials of ATI-501 and ATI-502 and two pivotal Phase 3 clinical trials of A-101 45% Topical Solution in 2019, and the corresponding reduction in personnel costs to support these programs. * General and administrative expenses were $5.6 million and $11.8 million for the quarter and six months ended June 30, 2020, respectively, compared to $7.5 million and $14.9 million for the quarter and six months ended June 30, 2019, respectively. * The quarter-over-quarter decrease of $1.9 million was primarily the result of lower personnel costs resulting from the Company’s decision to discontinue commercial operations in September 2019. * Loss from continuing operations was $11.6 million and $26.9 million for the quarter and six months ended June 30, 2020, respectively, compared to $43.7 million and $71.0 million for the quarter and six months ended June 30, 2019, respectively. Loss from discontinued operations was $27,000 and $0.3 million for the quarter and six months ended June 30, 2020, respectively, compared to $6.2 million and $16.5 million for the quarter and six months ended June 30, 2019, respectively.About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris' current beliefs and expectations.
- 08/07/2020
|
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
- Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/06/2020
|
ACTIA : Chiffre d’affaires du 2ème trimestre 2020
- Regulatory News: ACTIA (Paris:ATI) : IFRS, en M€ 2020* 2019 Var. 1er trimestre 117,1 134,4 <12,8%> 2ème trimestre 84,9 129,8 <34,6%> dont
- 08/05/2020
|
42% of Americans Feel Uncomfortable Paying Out-of-Pocket for Chronic Pain Treatment, ATI Physical Therapy National Survey Finds
|
Allegheny Technologies Inc (ATI) Q2 2020 Earnings Call Transcript | The Motley Fool
- ATI earnings call for the period ending June 30, 2020.
- 08/04/2020
|
Aclaris Therapeutics Inc (NASDAQ:ACRS) Short Interest Down 9.5% in July
- Aclaris Therapeutics Inc (NASDAQ:ACRS) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 1,240,000 shares, a decrease of 9.5% from the June 30th total of 1,370,000 shares. Approximately 4.0% of the company’s stock are sold short. Based on an average trading volume of […]
- 08/04/2020
|
ATI Announces Second Quarter 2020 Results
- ATI Announces Second Quarter 2020 Results
- 08/04/2020
|
Allegheny Technologies (ATI) Scheduled to Post Earnings on Tuesday
- Allegheny Technologies (NYSE:ATI) is set to release its earnings data before the market opens on Tuesday, August 4th. Analysts expect Allegheny Technologies to post earnings of ($0.11) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link. Allegheny Technologies (NYSE:ATI) last released its quarterly […]
- 08/02/2020
|
Cashing in super to buy property not the best idea
- Renting is likely to be the better option when seeking a holiday home than missing out on the income and growth of a substantial share portfolio.
- 07/28/2020
|
Two Sigma Advisers LP Sells 23,200 Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS)
- Two Sigma Advisers LP lessened its position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 40.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,700 shares of the biotechnology company’s stock after selling 23,200 shares during the period. Two […]
- 07/16/2020
|
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
- Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 07/08/2020
|
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). “We are very pleased to have achieved another development milestone with the submission of this IND and look forward to exploring the therapeutic potential of ATI-1777 in patients with moderate to severe AD,” said Dr. David Gordon, Chief Medical Officer of Aclaris. “ATI-1777 is designed to be active in the skin but rapidly metabolized in the systemic circulation, with the goal of developing a medicine that is efficacious in the treatment of AD while limiting systemic exposure.”
- 07/07/2020
|
Zacks: Brokerages Expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to Announce -$0.34 Earnings Per Share
- Equities analysts predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post ($0.34) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.35). Aclaris Therapeutics posted earnings of ($0.72) per share in the same quarter last year, which […]
- 07/04/2020
|
Is Aclaris Therapeutics, Inc. (ACRS) A Good Stock To Buy?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/26/2020
|
Aclaris Therapeutics (NASDAQ:ACRS) versus Aytu Bioscience (NASDAQ:AYTU) Financial Analysis
- Aclaris Therapeutics (NASDAQ:ACRS) and Aytu Bioscience (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Insider & Institutional Ownership 81.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, […]
- 06/24/2020
|
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 4.3%
- Aclaris Therapeutics Inc (NASDAQ:ACRS)’s share price dropped 4.3% during trading on Friday . The company traded as low as $1.55 and last traded at $1.57, approximately 8,317 shares changed hands during mid-day trading. A decline of 99% from the average daily volume of 720,054 shares. The stock had previously closed at $1.64. ACRS has been […]
- 06/21/2020
|
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
- Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
- 06/18/2020
|
P/E Ratio Insights for Aclaris Therapeutics
- Looking into the current session, Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares are trading at $1.76, after a 18.92% increase. Moreover, over the past month, the stock spiked by 37.50%, but in the past year, fell by 64.73%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently above from its 52 week low by 151.43%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Compared to the aggregate P/E ratio of the 0.66 in the Biotechnology industry, Aclaris Therapeutics Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * P/E Ratio Insights for Fulgent Genetics * P/E Ratio Insights for Moderna * P/E Ratio Insights for Energous(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/17/2020
|
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
- FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical.
- 06/17/2020
|
Aclaris Rips Higher Following FDA Approval Of Coronavirus Study
- Shares of micro-cap biopharma Aclaris Therapeutics Inc (NASDAQ: ACRS) were rallying Wednesday after the FDA gave its blessing for the company's investigational new drug...
- 06/17/2020
|
PS5 price and pre-orders: what we know about the Playstation 5 cost and when you can buy it
- Everything we know about the PS5 price so far
- 06/12/2020
|
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
- WAYNE, Pa., June 03, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for.
- 06/03/2020
|
Xbox One S vs. Xbox One X: Which should you buy?
- When it comes to Xbox, right now you have two different consoles to choose from. Which is better for you? Let's take a look.
- 05/28/2020
|
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
- WAYNE, Pa., May 26, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that.
- 05/26/2020
|
Charity manager gets on her bike for domestic abuse victims - The Wokingham Paper
- HEAVILY involved in the world of charities and fundraising, a woman is tackling a 26 marathon challenge in aid of domestic abuse victims.
- 05/16/2020
|
Now, give personal details while buying cold, cough and fever drugs
- The details of such customers has to be uploaded on the portal developed by the Food Safety and Drug Administration (FSDA) by the retail chemists in the state.
- 05/15/2020
|
Will Aclaris Therapeutics Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
- 05/12/2020
|
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
- Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 05/08/2020
|
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
- Projected Cash Runway into the First Quarter of 2022Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a.
- 05/07/2020
|
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2020
|
Bank of New York Mellon Corp Acquires 95,527 Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS)
- Bank of New York Mellon Corp boosted its position in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 76.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 219,779 shares of the biotechnology company’s stock after buying an additional 95,527 shares during the quarter. Bank of New […]
- 04/30/2020
|
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Zacks Investment Research to "Hold"
- Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists […]
- 04/16/2020
|
Does The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Share Price Fall With The Market?
- Anyone researching Aclaris Therapeutics, Inc. (NASDAQ:ACRS) might want to consider the historical volatility of the...
- 04/09/2020
|
Man Group plc Sells 2,438,827 Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS)
- Man Group plc reduced its holdings in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 65.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,295,966 shares of the biotechnology company’s stock after selling 2,438,827 shares during the period. Man Group plc owned about 3.13% of Aclaris Therapeutics worth […]
- 04/08/2020
|
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Zacks Investment Research to "Buy"
- Zacks Investment Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. The brokerage currently has $1.25 price objective on the biotechnology company’s stock. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, […]
- 04/07/2020
|
Aclaris (ACRS) Upgraded to Buy: Here's Why
- Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/06/2020
|
Wayne biopharma firm borrows $11M to fund new business strategy
- The funds will extend the 'cash runway' for a company that six months ago shifted its product development focus.
- 04/01/2020
|
Aclaris Therapeutics Secures $11 Million Term Loan Facility
- Aclaris Therapeutics, Inc. (CICN), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $11.0 million. Aclaris believes the proceeds from the loan, in combination with its existing cash, cash equivalents, and marketable securities, will be sufficient to fund its operations into the first quarter of 2022. The term loan requires interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through March 1, 2024.
- 03/31/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Edited Transcript of ACRS earnings conference call or presentation 25-Feb-20 10:00pm GMT
- Q4 2019 Aclaris Therapeutics Inc Earnings Call
- 03/17/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
- 02/26/2020
|
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
- Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 InhibitorProjected Cash Runway into the Third Quarter.
- 02/25/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
- 02/25/2020
|
Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Paid At A Competitive Rate?
- In 2012 Neal Walker was appointed CEO of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). This analysis aims first to...
- 02/24/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
- WAYNE, Pa., Feb. 19, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it.
- 02/19/2020
|
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
- WAYNE, Pa., Feb. 10, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that.
- 02/10/2020
|
What Company Will Eli Lilly Buy Next?
- Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
- 01/23/2020
|
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
- Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
- 01/13/2020
|
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
- Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
- 01/13/2020
|
The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
- 01/10/2020
|
Some Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Have Taken A Painful 94% Share Price Drop
- It is a pleasure to report that the Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is up 31% in the last quarter. But that...
- 01/10/2020
|
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
- • Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6• Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory.
- 01/09/2020
|
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
- Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent Milano to its board of directors, effective January 7, 2020. Vincent Milano has served as the President and Chief Executive Officer, and as a member of the board of directors, of Idera Pharmaceuticals, Inc., a publicly held biopharmaceutical company, since December 2014. Prior to joining Idera, between 1996 and 2014, Mr. Milano served in increasingly senior roles at ViroPharma Inc., a pharmaceutical company that was acquired by Shire Plc in 2014, most recently as Chairman, President and Chief Executive Officer from 2008 to 2014.
- 01/08/2020
|
Fake beauty news? ‘Wrinkles completely removed in 20 minutes’
- From the archive: Was this article in 1913 an early example of ‘native advertising’?
- 01/05/2020
|
Aclaris (ACRS) Upgraded to Buy: Here's Why
- Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/24/2019
|
How Artificial Intelligence is Used to Expedite Research
- Our underpaid MBAs spend a lot of time doing research here at Nanalyze. We want to be as comprehensive as possible to ensure that we’re bringing our lovely readers the best stories about technology and retail investing. But that takes time. There are close to two billion websites out there on the interwebs, so tracking down the most relevant and reliable information is like trying to find an honest broker on Wall Street. And good data costs money. For example, data firm CB Insights is the gold standard when it comes to market research, partly driven by machine learning algorithms,
- 06/23/2018
|
Microsoft Discontinues Kinect For Xbox One
- Microsoft has discontinued Kinect for Xbox One. The peripheral originally launched with every new Xbox One console.
- 10/25/2017
|
Check out this amazing homebrewed mixed reality hologram
- Mixed reality has been buzzing the past few weeks with a slew of Microsoft Hololens and Magic Leap announcements. Both companies seem poised to augment our realities over the next few years, but one developer isn’t willing to wait that long to have a pretty hologram floating in his room. Oliver Pavicevics has been working…
- 10/30/2015
|
